Roche's Obesity Drug Delivers 22.5% Weight Loss

Note: This section contains information in English only.
Source: Dukascopy Bank SA
Roche's experimental CT-388 achieved 22.5% weight loss in a Phase II trial, seeking to challenge Lilly and Novo in the $150B obesity market.
Back to articles

Actual Topics

Wed, 28 Jan 2026 09:30:04 GMT

SoftBank Eyes Bigger OpenAI Bet

SoftBank is in talks to invest up to $30B more in OpenAI, part of a funding round that could raise $100B and value the firm at $830B.

Tue, 27 Jan 2026 21:30:05 GMT

SoftBank Halts Switch Acquisition Talks

SoftBank ends $50B talks to buy Switch, slowing Masayoshi Son's Stargate AI plans for OpenAI data center expansion.

Subscribe to "Fundamental Analysis" feed

Subscribe
Per scoprire di più sulla piattaforma di Dukascopy Bank per Forex/CFD, sul SWFX ed altre informazioni relative al trading,
la preghiamo di contattarci o richiedere di essere contattato (callback request)
For further information regarding potential cooperation,
please call us or make callback request.
To learn more about Dukascopy Bank Binary Options / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
Per scoprire di più sulla piattaforma di Dukascopy Bank per Forex/CFD, sul SWFX ed altre informazioni relative al trading,
la preghiamo di contattarci o richiedere di essere contattato (callback request).
To learn more about Crypto Trading / CFD / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
To learn more about Business Introducer and other trading related information,
please call us or make callback request.
For further information regarding potential cooperation,
please call us or make callback request.